ABSTRACT
This study evaluated the effect of a prostaglandin F2? (PGF) analogue as an ovulatory stimulus in dairy cows and buffaloes raised in the Amazon biome. To this end, three experiments were performed in the state of Rondônia, located in the Amazon biome. In Experiment 1, 22 lactating dairy buffaloes received 2 mg of intramuscular (I.M.) estradiol benzoate (EB) on day 0 and an intravaginal progesterone-releasing device (CIDR) from day 0 to day 9 of the protocol. On days 8 and 9, all cows were given 500 ?g of I.M. d-cloprostenol (PGF analogue). On day 10, buffaloes were divided into two groups to receive 500 ?g of PGF (PGF group, n = 8) or no treatment (CTL group, n = 14), respectively. In Experiment 2, 16 lactating crossbred dairy cows (Holstein x Gir) received 2 mg of EB on day 0 and a CIDR insert from day 0 to day 8. On days 7 and 8, all cows were given 500 ?g of d-cloprostenol. On day 9, cows were divided into two groups to receive 500 ?g of d-cloprostenol (PGF group, n = 8) or no treatment (CTL group, n = 8), respectively. In Experiment 3, 16 lactating crossbred dairy cows (Holstein x Gir) were handled and treated similarly as in Experiment 2, although cows did not receive d-cloprostenol on day 8. Single-point outcome variables were analyzed using one-way analysis of variance (ANOVA), while proportions with dichotomous outcomes were analyzed with the chi-square test.
O objetivo deste estudo foi avaliar o efeito de um análogo de prostaglandina F2α (PGF) como indutor ovulatório em vacas leiteiras e búfalas. Para este fim, três experimentos foram realizados no estado de Rondônia, localizado no bioma Amazônia. No Experimento 1, 22 búfalas leiteiras em lactação receberam 2 mg de benzoato de estradiol (EB) im, no Dia 0 e um dispositivo intravaginal de liberação de progesterona (CIDR) do Dia 0 ao Dia 9 do protocolo. Nos Dias 8 e 9, todas as vacas receberam 150μg de d-Cloprostenol (análogo PGF), im. No Dia 10, as búfalas foram divididas em dois grupos para receber 150μg de PGF (Grupo PGF, n = 8) ou nenhum tratamento (Grupo CTL, n = 14). No experimento 2, 16 vacas leiteiras mestiças (Holandês x Gir) receberam 2 mg de EB no Dia 0 e um dispositivo intravaginal (CIDR) do Dia 0 ao Dia 8. Nos Dias 7 e 8 todas as vacas receberam 150μg de d-Cloprostenol. No Dia 9, as vacas foram divididas em dois grupos para receber 150μg de d-Cloprostenol (Grupo PGF, n = 8) ou nenhum tratamento (Grupo CTL, n = 8). No Experimento 3, 16 vacas leiteiras mestiças (Holandês x Gir) foram tratadas da mesma forma que no Experimento 2, porém, as vacas não receberam d-Cloprostenol no Dia 8. Variáveis quantitativas foram analisados por análise de variância - one-way ANOVA e variáveis dicotômicas foram analisados pelo teste do qui-quadrado. No Experimento 1, não houve diferença (P = 0,30) na taxa de ovulação entre os grupos, em média 68% das búfalas ovularam após o tratamento. Além disso, não houve diferença entre os grupos no intervalo de ovulação (P = 0,61) e no diâmetro do folículo pré-ovulatório (P = 0,47). No Experimento 2, apenas uma vaca do Grupo PG não ovulou. Não houve diferenças no intervalo de ovulação entre os grupos CTL e PG (P = 0,69). Em média, a ovulação ocorreu 82 horas após a remoção do CIDR. No Experimento 3, vacas tratadas com PGF ovularam antes do Grupo CTL (62,5 ± 5,8 vs 94,5 ± 13,5 h; P = 0,05). Coletivamente, esses resultados sugeriram que a PGF antecipa a ovulação em vacas leiteiras em lactação, porém seu efeito não foi observado em búfalas.
Subject(s)
Female , Animals , Buffaloes/embryology , Cloprostenol/chemistry , Dinoprost/administration & dosage , Livestock/embryology , Hormones , Lactation , Ovulation , Progesterone/analysis , Benzoates/administration & dosage , Benzoates/analysisABSTRACT
This study evaluated the effect of a prostaglandin F2? (PGF) analogue as an ovulatory stimulus in dairy cows and buffaloes raised in the Amazon biome. To this end, three experiments were performed in the state of Rondônia, located in the Amazon biome. In Experiment 1, 22 lactating dairy buffaloes received 2 mg of intramuscular (I.M.) estradiol benzoate (EB) on day 0 and an intravaginal progesterone-releasing device (CIDR) from day 0 to day 9 of the protocol. On days 8 and 9, all cows were given 500 ?g of I.M. d-cloprostenol (PGF analogue). On day 10, buffaloes were divided into two groups to receive 500 ?g of PGF (PGF group, n = 8) or no treatment (CTL group, n = 14), respectively. In Experiment 2, 16 lactating crossbred dairy cows (Holstein x Gir) received 2 mg of EB on day 0 and a CIDR insert from day 0 to day 8. On days 7 and 8, all cows were given 500 ?g of d-cloprostenol. On day 9, cows were divided into two groups to receive 500 ?g of d-cloprostenol (PGF group, n = 8) or no treatment (CTL group, n = 8), respectively. In Experiment 3, 16 lactating crossbred dairy cows (Holstein x Gir) were handled and treated similarly as in Experiment 2, although cows did not receive d-cloprostenol on day 8. Single-point outcome variables were analyzed using one-way analysis of variance (ANOVA), while proportions with dichotomous outcomes were analyzed with the chi-square test.(AU)
O objetivo deste estudo foi avaliar o efeito de um análogo de prostaglandina F2α (PGF) como indutor ovulatório em vacas leiteiras e búfalas. Para este fim, três experimentos foram realizados no estado de Rondônia, localizado no bioma Amazônia. No Experimento 1, 22 búfalas leiteiras em lactação receberam 2 mg de benzoato de estradiol (EB) im, no Dia 0 e um dispositivo intravaginal de liberação de progesterona (CIDR) do Dia 0 ao Dia 9 do protocolo. Nos Dias 8 e 9, todas as vacas receberam 150μg de d-Cloprostenol (análogo PGF), im. No Dia 10, as búfalas foram divididas em dois grupos para receber 150μg de PGF (Grupo PGF, n = 8) ou nenhum tratamento (Grupo CTL, n = 14). No experimento 2, 16 vacas leiteiras mestiças (Holandês x Gir) receberam 2 mg de EB no Dia 0 e um dispositivo intravaginal (CIDR) do Dia 0 ao Dia 8. Nos Dias 7 e 8 todas as vacas receberam 150μg de d-Cloprostenol. No Dia 9, as vacas foram divididas em dois grupos para receber 150μg de d-Cloprostenol (Grupo PGF, n = 8) ou nenhum tratamento (Grupo CTL, n = 8). No Experimento 3, 16 vacas leiteiras mestiças (Holandês x Gir) foram tratadas da mesma forma que no Experimento 2, porém, as vacas não receberam d-Cloprostenol no Dia 8. Variáveis quantitativas foram analisados por análise de variância - one-way ANOVA e variáveis dicotômicas foram analisados pelo teste do qui-quadrado. No Experimento 1, não houve diferença (P = 0,30) na taxa de ovulação entre os grupos, em média 68% das búfalas ovularam após o tratamento. Além disso, não houve diferença entre os grupos no intervalo de ovulação (P = 0,61) e no diâmetro do folículo pré-ovulatório (P = 0,47). No Experimento 2, apenas uma vaca do Grupo PG não ovulou. Não houve diferenças no intervalo de ovulação entre os grupos CTL e PG (P = 0,69). Em média, a ovulação ocorreu 82 horas após a remoção do CIDR. No Experimento 3, vacas tratadas com PGF ovularam antes do Grupo CTL (62,5 ± 5,8 vs 94,5 ± 13,5 h; P = 0,05). Coletivamente, esses resultados sugeriram que a PGF antecipa a ovulação em vacas leiteiras em lactação, porém seu efeito não foi observado em búfalas.(AU)
Subject(s)
Animals , Female , Dinoprost/administration & dosage , Ovulation , Livestock/embryology , Buffaloes/embryology , Hormones , Progesterone/analysis , Lactation , Cloprostenol/chemistry , Benzoates/administration & dosage , Benzoates/analysisABSTRACT
BACKGROUND: The stability of ophthalmic preparations in multidose containers is influenced by the preservative as well as the stability of the active ingredient. Unstable drugs may require refrigeration to preserve their active ingredient level and they are more likely to degrade over time, therefore becoming more susceptible to degradation based on patient mishandling. The purpose of this study was to determine the degree of molecular degradation that occurs in bimatoprost and latanoprost in a patient-use setting. METHODS: This was an open-label, laboratory evaluation of the relative stability of bimatoprost and latanoprost. Patients presently using bimatoprost (n = 31) or latanoprost (n = 34) were identified at 2 clinical sites in Brazil. Patients were instructed to use and store their drops as usual and return all used medication bottles between day 28 and day 34 after opening. RESULTS: Bimatoprost demonstrated no degradation, but latanoprost degraded at various levels. The mean age of bimatoprost was 43.0 +/- 3.4 days and the mean age of latanoprost was 43.9 +/- 2.8 days (P = .072). The mean percentage of labeled concentration was 103.7% in the bimatoprost bottles and 88.1% in the latanoprost bottles (P < 001). CONCLUSION: This study showed that bimatoprost maintained > or =100% concentration throughout the study period while latanoprost did not.
Subject(s)
Amides/chemistry , Antihypertensive Agents/chemistry , Cloprostenol/analogs & derivatives , Drug Stability , Glaucoma/drug therapy , Prostaglandins F, Synthetic/chemistry , Adult , Amides/administration & dosage , Amides/standards , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/standards , Bimatoprost , Cloprostenol/administration & dosage , Cloprostenol/chemistry , Cloprostenol/standards , Drug Packaging , Follow-Up Studies , Humans , Intraocular Pressure/drug effects , Latanoprost , Ophthalmic Solutions , Prostaglandins F, Synthetic/administration & dosage , Prostaglandins F, Synthetic/standards , Retrospective Studies , Seasons , Temperature , Time FactorsABSTRACT
The chirality of drugs, with particular reference to agents used in veterinary medicine, is reviewed. Basic concepts of chirality and aspects of the methodology for the separation of enantiomers are considered. Chiral compounds are in common use in animals and their pharmacological actions and side-effects (pharmacodynamics) and absorption into and fate within the body (pharmacokinetics) are of fundamental importance; pharmacodynamic and pharmacokinetic properties of enantiomeric pairs commonly differ and this has major implications for their effective and safe therapeutic use. As examples of the particular significance of chirality in veterinary medicine, the following drug classes are reviewed; benzimidazole anthelmintics, cloprostenol, verapamil, ketamine, halogenated hydrocarbon anaesthetics and 2-arylpropionic acid anti-inflammatory drugs. The implications of chirality for drug product development and approval by registration authorities are discussed.